Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00058253 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
A Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Recurrent Prostate Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT00058253 is a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Recurrent Prostate Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 80 participants, below the 500-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00058253, a Phase 1 study of Unspecified Adult Solid Tumor, Protocol Specific and Recurrent Prostate Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial is studying the side effects and best dose of combination chemotherapy in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as docetaxel and 17-N-allylamino-17-demethoxygeldanamycin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
Conditions Studied
Interventions
- DRUG docetaxel
- DRUG tanespimycin
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2003-02 |
| Est. Completion | 2010-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00058253
The ClinicalTrials.gov registry entry for NCT00058253 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 500-participant average among 83 other Unspecified Adult Solid Tumor, Protocol Specific trials with a reported enrollment target (84% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 2 interventions - of which docetaxel is the first listed.
NCT00058253 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00058253 about?
NCT00058253 is a clinical study titled "Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors". This phase I trial is studying the side effects and best dose of combination chemotherapy in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as docetaxel and 17-N-allylamino-17-demethoxygeldanamycin, work in different ways to stop tumor cells from div...
What is the current status of trial NCT00058253?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2003-02. Estimated completion is 2010-03.
What conditions does trial NCT00058253 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific, Recurrent Prostate Cancer, Stage IV Prostate Cancer.
What interventions are being tested in trial NCT00058253?
The interventions under investigation include: docetaxel (DRUG), tanespimycin (DRUG).
Who is sponsoring clinical trial NCT00058253?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00058253 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
ACTIVE NOT RECRUITING · Phase 1
-
Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
COMPLETED · Phase 1
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
COMPLETED · Phase 1
-
Indole-3-Carbinol in Preventing Cancer in Healthy Participants
COMPLETED · Phase 1
-
Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
Explore more on PlainTrial
Unspecified Adult Solid Tumor, Protocol Specific
All registered trials for this condition
Recurrent Prostate Cancer
All registered trials for this condition
New York
All trials with a study site in New York
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.